Literature DB >> 1630814

Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.

B Ruggeri1, S Y Zhang, J Caamano, M DiRado, S D Flynn, A J Klein-Szanto.   

Abstract

The molecular pathology of human pancreatic cancer is poorly understood, particularly with regard to the role of known tumor-suppressor genes. We have examined the expression of the p53 and Rb-1 tumor-suppressor genes in seven human pancreatic carcinoma cell lines and 10 primary pancreatic carcinomas. Examination of the Rb-1 gene by Northern hybridization and immunoprecipitation analyses revealed the absence of Rb-1 protein expression in two cell lines. Moreover, regions of absent nuclear staining in two primary pancreatic carcinomas were detected by immunohistochemical analysis. Investigation of p53 by Southern, Northern, immunohistochemical and immunoprecipitation analyses revealed multiple abnormalities, including gross rearrangements in two cell lines, the absence of detectable p53 transcript in two cell lines and a truncated transcript in one line. Six cell lines overexpressed p53 protein, while one line revealed the absence of p53 product by immunohistochemical and immunoprecipitation analyses. Sequence analysis of exons 5-8 of the p53 gene confirmed these analyses, revealing missense mutations in all seven cell lines in codons 181, 220, 248, 249, 265, 272 and 273. Of 10 mutations identified, nine were transitions and 50% were in codon 273. Immunohistochemical analyses of frozen primary pancreatic carcinomas revealed positive nuclear staining for p53 in 40% of cases. Mutations were identified in codons 238 and 286 and in intron 9 in several representative specimens. Alterations in the p53 and Rb-1 genes may be important features in the development of human pancreatic cancer.

Entities:  

Mesh:

Year:  1992        PMID: 1630814

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

Review 3.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

4.  Genetic progression and divergence in pancreatic carcinoma.

Authors:  M Yamano; H Fujii; T Takagaki; N Kadowaki; H Watanabe; T Shirai
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 5.  Proteomics analysis of bodily fluids in pancreatic cancer.

Authors:  Sheng Pan; Teresa A Brentnall; Ru Chen
Journal:  Proteomics       Date:  2015-04-27       Impact factor: 3.984

Review 6.  Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.

Authors:  Ibrahim H Sahin; Christine A Iacobuzio-Donahue; Eileen M O'Reilly
Journal:  Expert Opin Ther Targets       Date:  2015-10-06       Impact factor: 6.902

7.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.

Authors:  P Laurent-Puig; R Lubin; S Semhoun-Ducloux; G Pelletier; C Fourre; M Ducreux; M J Briantais; C Buffet; T Soussi
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

8.  Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells.

Authors:  Lauren Friedman; Li Lin; Sarah Ball; Tanios Bekaii-Saab; James Fuchs; Pui-Kai Li; Chenglong Li; Jiayuh Lin
Journal:  Anticancer Drugs       Date:  2009-07       Impact factor: 2.248

9.  Efficacy of p120 antisense-mediated therapy for pancreatic cancer.

Authors:  J W Freeman; W E Strodel; P C McGrath
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

Review 10.  Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors.

Authors:  H Friess; P Berberat; M Schilling; J Kunz; M Korc; M W Büchler
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.